|
|||||
|
|
Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis |
|
| Authors: | De Savi Chris Pape Andrew Sawyer Yvonne Milne David Davies Chris Cumming John G Ting Attilla Lamont Scott Smith Peter D Tart Jonathon Page Ken Moore Peter |
| Institution: | a Respiratory and Inflammation Research Area, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK b Oncology Innovative Medicines, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK |
| Abstract: | A new achiral class of N-hydroxyformamide inhibitor of both ADAM-TS4 and ADAM-TS5, 2 has been discovered through modification of the complex P1 group present in historical inhibitors 1. This structural change improved the DMPK properties and greatly simplified the synthesis whilst maintaining excellent cross-MMP selectivity profiles. Investigation of structure-activity and structure-property relationships in the P1 group resulted in both ADAM-TS4 selective and mixed ADAM-TS4/5 inhibitors. This led to the identification of a pre-clinical candidate with excellent bioavailability across three species and predicting once daily dosing kinetics. |
| Keywords: | ADAM-TS4 ADAM-TS5 Aggrecanase Reverse hydroxamate Osteoarthritis |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ | |